The 14th meeting of the 10th board of directors and the 9th meeting of the 9th board of supervisors held to review and approve the annual work report and other relevant proposals
Release time:
2020-07-31
News from our newspaper 4# April 24 , Chairman Jiang Xiaomeng of the Group Company presided over the 14 meeting of the 10th Board of Directors of the Company, deliberated and approved 2019 Board of Directors Report, 2019 General Manager Business Report, 2019 Annual Report and other 14 related reports and proposals.
General Manager's report points out that 2019 is the first year of the implementation of the group's new five-year strategic development plan (2019-2023 ) and the new three-year business plan (2019-2021) for each business sector. The management team focuses on the general working policy of "innovation and reform, integration and promotion, scientific layout and steady development, orderly carry out all kinds of operation and management work, and better fulfill the business objectives set by the board of directors at the beginning of the year. In the whole year, the company realized a total operating income of 35.48 .8 billion yuan, up 5.51% year on year. Net profit attributable to shareholders reached 7.25 .2 billion yuan, earnings per share reached 2.11 yuan, up 23.14% year on year, reaching a new record high. At the end of the year, total assets reached 54.75 .8 billion yuan, up 11.71% year on year; net assets attributable to shareholders were 37.89 .2 billion yuan, up 19.81% year on year.
During the reporting period, the company's two main businesses have achieved great development, benefiting from the further promotion of supply-side structural reform, 2019 cement industry operation is generally stable, industry efficiency further improved. During the reporting period, the company made new progress in the construction of cement projects, completed the acquisition, capital increase and name change of Guizhou Mingchuan (Guizhou Huangping Jianfeng Cement Co., Ltd.), and continued to invest in the construction of its new dry cement production line with a daily output of 4500 tons (with waste heat power generation). During the reporting period, the company completed the construction investment of 4.47 .4 billion yuan, and the project progressed smoothly; yunnan Jianfeng invested ,500 yuan to participate in the establishment of Yunnan Jianfeng Da Zhan Cement Co., Ltd., accounting for 10% of its shares, further expanding the company's cement business segment. During the reporting period, Daye Peak and Yunnan Peak continued to carry out in-depth "three reductions and three improvements" activities, steadily implemented standardized management, vigorously introduced advanced and applicable technologies to implement technological transformation, and continuously improved the labor productivity of enterprises while strictly controlling production costs. The leading position in the regional market has been further consolidated and enhanced, 2019 Daye Peak realized net profit 2.98 .2 billion yuan, Yunnan Peak realized net profit 2.71 .4 billion yuan, the company's cement sector operating performance reached a new record high.
2019 was a year of constant volatility and accelerated differentiation in the pharmaceutical market, with the introduction of new pharmaceutical policies to promote the development of the entire industry in the direction of concentration, innovation and high quality. During the reporting period, in order to fully cope with the changes in the industry and enrich the company's product line, Jianfeng Pharmaceutical further strengthened its product research and development and innovation. More than 20 research projects were under development, which were respectively in various stages of preclinical research, clinical research, pre-production research or production application. Olopatadine Hydrochloride Eye Drops obtained the drug registration approval and was put on the market. Paroxetine Hydrochloride Tablets passed the consistency evaluation smoothly, the drug supplement application approval was obtained in , 2020, , , 3, and July; Complete the registration and consistency evaluation declaration of cefmenoxime hydrochloride raw materials and injections; Complete the registration and filing of imatinib mesylate raw materials and tablet registration declaration. 2019 , Jianfeng Pharmaceutical and its subsidiaries made new progress in a number of technological transformation and engineering construction. The construction of the annual production of 20 .9 billion solid preparations (internationalization) project in Jinxi Production Base of Jianfeng Pharmaceutical is progressing smoothly. The project is listed as a major industrial project in Zhejiang Province in 2019 and a key technological transformation project in Jinhua City in 2020 ; the implementation of Anhui Beika and Anhui Zhongwang Phase II technological transformation projects will upgrade and on the basis of their existing products to become the company's comprehensive research and development and production base for raw materials, pharmaceutical intermediates and pesticides, and actively promote the industrial upgrading strategy of the integration of peak pharmaceutical raw materials and preparations. On the day of
9 , and reviewed and approved related reports and proposals such as the work report of the board of supervisors 2019 , the financial final accounts report of 2019 , and the profit distribution plan of 2019 . (Remaining Fruit)
More information
On the afternoon of June 9, Peak Cable Company organized all employees to learn fire fighting knowledge and conducted fire fighting and emergency escape drills. Since June, the subordinate enterprises of the company have organized training, learning and drills related to production safety according to their own characteristics and combined with the actual work. Safety production month series of activities carried out in an orderly manner.
2022
06-13
Spike Postdoctoral Research Papers on International Frontier Journals
Recently, good news came from the postdoctoral workstation of Jianfeng Pharmaceutical. Under the guidance of workstation mentor Jiang Xiaomeng, associate researcher Yang Xiaoxiao has made new progress in the treatment of alcoholic liver disease. The relevant research results "Roxadustat, a hypoxia-inducible factor 1a activator, attenuates both long- and short-term alcohol induced alcoholic liver disease" were published in the internationally renowned academic journal "Frontiers in Pharmacology. This journal is a frontier journal in the field of international pharmacy, mainly publishing academic papers and information on basic and clinical pharmacology, medicinal chemistry, pharmacology and toxicology.
2022
06-01
Daye Peak QC Achievements Won the Third Prize of Huangshi City
On May 7, Huangshi City Quality Strong City Working Committee organized a 2022 QC Results Conference. The QC project of "Technical Transformation of Ore Limestone Batching System" of Daye Peak Cement Company won the third prize.
2022
06-01
On April 28, Dalian Commodity Exchange held an online working meeting to announce the results of the 2021 excellent delivery warehouse and delivery warehouse excellent futures personnel selection, peak international trading company won the 2021 "excellent designated delivery warehouse" title, futures commissioner Ruan Weihang won the "excellent futures personnel" title.
2022
06-01
Cranberry extract combination identification detection method won the invention patent
After cranberry extract products were included in the "Zhejiang Province Key High-tech Product Development Project Plan" in 2021, Jianfeng Health Technology Company recently obtained an invention patent for the identification and detection method of cranberry extract. This new combined identification and detection method developed by Jianfeng Health identifies whether catechin or procyanidin B2 is added in cranberry extract by thin layer analysis, and then detects the unique A- type procyanidin and its chromatographic distribution in cranberry extract by high performance liquid chromatography, so as to improve the accuracy of product judgment. The identification method has the characteristics of accurate results and short detection time, which is of great significance to standardize the cranberry extract market and promote the healthy development of the industry, and has been unanimously recognized by peers.
2022
05-20
Daye Peak Manufacturing Department Won the Title of "Worker Pioneer" in Hubei Province
A few days ago, the manufacturing department of Daye Peak Cement Company was awarded the title of "Worker Pioneer" by the Hubei Provincial Federation of Trade Unions. Daye Jianfeng Manufacturing Department not only continued to actively explore and achieved good results in energy saving and consumption reduction, technological transformation, product quality process control, and economic responsibility system to guide management, but also improved Daye Jianfeng's overall operation level and won Huangshi City The seventh "Mayor Quality Award" created conditions and was fully affirmed by government departments at all levels.
2022
05-20
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page